Pesquisa
Educação
Soluções
Entrar
PT
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
The virology Core at the HIV Drug Resistance Program
Ann Wiegand has not added Biography.
If you are Ann Wiegand and would like to personalize this page please email our Author Liaison for assistance.
Depletion of latent HIV-1 infection in vivo: a proof-of-concept study.
Lancet Aug 13-19, 2005 | Pubmed ID: 16099290
New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma.
Journal of clinical microbiology Oct, 2003 | Pubmed ID: 14532178
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia.
PLoS pathogens Apr, 2007 | Pubmed ID: 17411338
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy.
Proceedings of the National Academy of Sciences of the United States of America Mar, 2008 | Pubmed ID: 18332425
Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells.
AIDS (London, England) Jun, 2008 | Pubmed ID: 18525258
Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control.
Immunity Dec, 2008 | Pubmed ID: 19062316
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.
The Journal of infectious diseases Mar, 2009 | Pubmed ID: 19191590
Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy.
The Journal of infectious diseases Jun, 2009 | Pubmed ID: 19432547
Persistent low-level viremia in HIV-1 elite controllers and relationship to immunologic parameters.
The Journal of infectious diseases Sep, 2009 | Pubmed ID: 19656066
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.
The Journal of infectious diseases Mar, 2010 | Pubmed ID: 20102272
Antiretroviral intensification and valproic acid lack sustained effect on residual HIV-1 viremia or resting CD4+ cell infection.
PloS one , 2010 | Pubmed ID: 20186346
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.
PLoS medicine , 2010 | Pubmed ID: 20711481
HIV-1 continues to replicate and evolve in patients with natural control of HIV infection.
Journal of virology Dec, 2010 | Pubmed ID: 20926564
Clonal sequences recovered from plasma from patients with residual HIV-1 viremia and on intensified antiretroviral therapy are identical to replicating viral RNAs recovered from circulating resting CD4+ T cells.
Journal of virology May, 2011 | Pubmed ID: 21367910
No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1-Infected Patients Receiving Antiretroviral Therapy.
Journal of acquired immune deficiency syndromes (1999) Mar, 2012 | Pubmed ID: 22083073
Restricted Replication of Xenotropic Murine Leukemia Virus-Related Virus in Pigtailed Macaques.
Journal of virology Jan, 2012 | Pubmed ID: 22238316
NCI-Frederick
Helene Mens1,
Mary Kearney1,
Ann Wiegand1,
Jonathan Spindler1,
Frank Maldarelli1,
John W. Mellors2,
John M. Coffin3
1The virology Core at the HIV Drug Resistance Program, NCI-Frederick,
2Division of Infectious Diseases, University of Pittsburgh,
3Department of Molecular Biology and Microbiology, Tuffts University
Privacidade
Termos de uso
Políticas
Entre em contato
recomende à biblioteca
Newsletter
JoVE Journal
Coleções de métodos
JoVE Encyclopedia of Experiments
Arquivo
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
Centro de Recursos para Docentes
Autores
Bibliotecários
Acesso
SOBRE A JoVE
Copyright © 2024 MyJoVE Corporation. Todos os direitos reservados